JLJi Hyung Lee

Ji Hyung Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ji Hyung Lee has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cerebrospinal fluid homocysteine, but not plasma homocysteine, is associated with markers of tau pathology and neurodegeneration

    by Ji Hyung Lee, Geun Hui Won, Sang-Ick Lee, Chul-Jin Shin, Jung-Woo Son, Siekyeong Kim, Gawon Ju, Seungwon Chung, Joon Hyung Jung, For The Alzheimer'S Disease Neuroimaging Initiative

    Background: Growing evidence links cardiovascular health to Alzheimer's disease (AD). While elevated plasma homocysteine (Hcy) is associated with cognitive decline, the relationship between cerebrospinal fluid (CSF) Hcy and the core pathological biomarkers of AD remains unclear. Objective: This study aimed to investigate the associations of CSF Hcy and plasma Hcy with CSF amyloid-β (Aβ 42 ), phosphorylated tau (p-tau), and total tau (t-tau). Methods: A total of 294 non-demented participants (110 cognitively normal, 184 with mild cognitive impairment) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database were analyzed. Multivariate linear regression was used to analyze the relationships between CSF and plasma Hcy levels and CSF Aβ 42 , phosphorylated tau (p-tau), and total tau (t-tau). Logistic regression analyses assessed the association between Hcy levels and Aβ 42 positivity, tau positivity, and neurodegeneration positivity. Results: CSF Hcy levels showed significant positive associations with CSF p-tau and t-tau, as well as tau and neurodegeneration positivity. In contrast, no significant association was found between CSF Hcy and Aβ 42 pathology. Notably, plasma Hcy was not associated with any AD-related biomarkers. Conclusions: CSF Hcy, rather than plasma Hcy, was associated with markers of tau pathology and neurodegeneration in non-demented older adults. These findings suggest that CSF Hcy may be more closely associated with tau-related pathological processes during the pre-dementia stages of AD. Further research is needed to explore the mechanisms underlying these associations.

  • DTI-ALPS index as a predictor of cognitive decline over 1 year

    by Joo Jungwon, Ji Hyung Lee, Chi-Hoon Choi, Jeonghwan Lee

    Purpose Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and impaired daily functioning. The glymphatic system removes neurotoxic waste, including amyloid-beta (Aβ), an important factor in AD pathogenesis. This study used the Diffusion Tensor Imaging Analysis Along the Perivascular Space (DTI-ALPS) index, which reflects glymphatic function, to explore its relationship with cognitive decline in patients with probable AD. Methods We conducted a longitudinal study of 16 participants aged 60–79 years with probable AD who were evaluated using the Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE). Glymphatic function was assessed using the DTI-ALPS index; plasma Aβ 42/40 ratios were measured to account for amyloid pathology. The relationship between the DTI-ALPS index and baseline cognitive function was analyzed using multiple regression models adjusted for age, sex, and plasma Aβ 42/40 ratios. Associations between the DTI-ALPS index and cognitive decline over 1 year were assessed by a model using the percentage change in the MMSE z-score as the outcome variable. Results Higher DTI-ALPS index was significantly associated with better baseline cognitive function as assessed by MMSE (standardized beta = 1.17, p < 0.001) and lower clinical severity as assessed by CDR (standardized beta = − 1.00, p = 0.006). Over the 1-year follow-up, greater baseline DTI-ALPS index values were associated with less cognitive decline (standardized beta = − 0.85, p = 0.018). Conclusion Our findings suggest that DTI-ALPS index is associated with cognitive performance and is a biomarker for predicting cognitive decline in AD. Future studies should consider larger sample sizes and longer follow-up periods to validate these findings.